A5022661953- Atrial Fibrillation Management and Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Arrhythmias and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pharmaceutical Economics and Policy
- Renal cell carcinoma treatment
- Cardiac Valve Diseases and Treatments
- Clostridium difficile and Clostridium perfringens research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cardiac electrophysiology and arrhythmias
- Innovation Policy and R&D
- Polyomavirus and related diseases
- Liver Disease and Transplantation
- Nosocomial Infections in ICU
- Cardiac pacing and defibrillation studies
- Sustainable Development and Environmental Policy
- Mitochondrial Function and Pathology
- Lung Cancer Treatments and Mutations
- Economic, financial, and policy analysis
- Cardiac, Anesthesia and Surgical Outcomes
- Mechanical Circulatory Support Devices
- Genomics and Rare Diseases
- Microscopic Colitis
- Respiratory and Cough-Related Research
- Adolescent and Pediatric Healthcare
University of York
2023-2024
Leeds and York Partnership NHS Foundation Trust
2021-2024
Introduction Three recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrial arrhythmia recurrence in patients symptomatic paroxysmal fibrillation (PAF) compared antiarrhythmic drug (AAD) therapy. The aim of this study was to evaluate the cost-effectiveness first-line AADs for treating PAF English National Health Service (NHS) setting. Methods Individual patient-level data from 703 participants...
The EARLY-AF (NCT02825979), STOP AF First (NCT03118518), and Cryo-FIRST (NCT01803438) randomised controlled trials (RCTs) demonstrated that cryoballoon pulmonary vein isolation reduces atrial fibrillation (AF) recurrence compared with antiarrhythmic drugs (AADs) in patients symptomatic paroxysmal (PAF). present study developed a cost-effectiveness model (CEM) of first-line cryoablation AADs for PAF, from the Canadian health care payer's perspective. Data 3 RCTs were analysed to estimate key...
Idiopathic Pulmonary Fibrosis (IPF) is a rare disease that causes shortness of breath, dry cough, and tiredness. While there no cure for IPF, current therapeutic treatments aim to slow lung degeneration while managing side effects. There little known about patient experience attitude with regards their medication.
Objectives To assess the cost-effectiveness of transarterial radioembolization (TARE) versus conventional chemoembolization (cTACE) and drug-eluting beads (DEE-TACE) for patients with unresectable early- to intermediate-stage hepatocellular carcinoma (HCC).Design A cohort-based Markov model a five-year time horizon was developed evaluate three embolization treatments. Upon entering model, HCC received either TARE or one two other Patients remained in "watch wait" state tumor downstaging that...
Abstract Background As demonstrated in three randomized clinical trials (RCTs), initial rhythm control with first-line pulmonary vein isolation (PVI) using cryoballoon ablation decreases atrial arrhythmia recurrence compared to antiarrhythmic drug (AAD) therapy patients symptomatic paroxysmal fibrillation (PAF). Purpose To assess the cost-effectiveness of cryoablation versus AADs a Danish healthcare setting. Methods Data from 703 participants PAF enrolled into Cryo-FIRST, STOP AF First and...
Transcatheter aortic valve implantation (TAVI) has shown similar or improved clinical outcomes compared with surgical replacement (SAVR) in patients symptomatic severe stenosis at low risk for mortality. This cost-utility analysis TAVI SAPIEN 3 versus SAVR of mortality from the perspective Swedish healthcare system.
An economic model was developed with guidance from the National Institute for Health and Care Excellence (NICE) 'Managing Common Infections' (MCI) Committee to evaluate cost effectiveness of different antibiotic treatment sequences treating Clostridioides difficile infection (CDI) in England. The consisted a 90-day decision tree followed by lifetime cohort Markov model. Efficacy data were taken network meta-analysis published literature, while cost, utility mortality literature. A sequence...
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and ultimately fatal lung disease that, while rare, has seen incidence rise over time. There no cure for IPF other than transplant, though two antifibrotic (AF) drugs do exist to slow progression. While these are efficacious, they both associated with differing profiles of adverse events. This study aimed elicit patient, caregiver pulmonologist preferences on the treatment AFs via discrete choice experiment (DCE).
Abstract Funding Acknowledgements Type of funding sources: Other. Main source(s): This cost-effectiveness study was funded by Medtronic Background The UK National Institute Care Excellence (NICE) recommend the use pulmonary vein isolation (PVI) to treat paroxysmal atrial fibrillation (PAF) in those who have not responded drug treatment. Recently, three randomized controlled trials demonstrated that as an initial rhythm control strategy, PVI with cryoballoon ablation, reduces arrhythmia...
Abstract Background Three recent randomized controlled trials demonstrated that, in patients with symptomatic paroxysmal atrial fibrillation (PAF), first-line pulmonary vein isolation (PVI) cryoballoon ablation reduces arrhythmia recurrence when compared to initial antiarrhythmic drug (AAD) therapy. Purpose To evaluate the cost-effectiveness of rhythm control therapy from a German healthcare service payer perspective. Methods The model (CEM) structure consisted hybrid decision tree and...